Strong Revenue Growth
Total revenue for Q3 2024 was $16.5 million, reflecting a 25% increase over the prior year period.
Increase in Recurring Revenue
Annual recurring revenue at the end of Q3 2024 was $53.5 million, up 25% from the previous year.
Successful Acquisitions
Completed acquisitions of MedCurrent and Strata Health, adding a combined $14.6 million to ARR, with Strata Health being the largest transaction in the company's history.
Cash Reserves and No Debt
As of September 30, 2024, the company reported cash on hand of $81.4 million and no debt.
High Adjusted EBITDA Margin
The adjusted EBITDA for Q3 2024 was $4.6 million, with a margin of 28%.